Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Posted by Emily Schoerning on Mar 14th, 2025

Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 301,300 shares, a drop of 68.4% from the February 13th total of 952,800 shares. Currently, 3.8% of the company’s stock are sold short. Based on an average daily trading volume, of 1,530,000 shares, the days-to-cover ratio is currently 0.2 days.

Dominari Stock Performance

Shares of NASDAQ:DOMH traded down $0.54 during mid-day trading on Friday, hitting $4.71. 1,032,761 shares of the company traded hands, compared to its average volume of 2,048,626. The firm has a market cap of $51.40 million, a P/E ratio of -1.22 and a beta of 1.08. Dominari has a 52-week low of $0.83 and a 52-week high of $13.58. The firm’s 50 day simple moving average is $4.77 and its 200 day simple moving average is $2.76.

Dominari Dividend Announcement

The business also recently announced a dividend, which was paid on Monday, March 3rd. Investors of record on Monday, February 24th were issued a dividend of $0.32 per share. The ex-dividend date was Monday, February 24th.

Institutional Investors Weigh In On Dominari

A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC boosted its holdings in shares of Dominari Holdings Inc. (NASDAQ:DOMH – Free Report) by 20.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,326 shares of the company’s stock after purchasing an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned approximately 0.89% of Dominari worth $55,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.48% of the company’s stock.

Dominari Company Profile

(Get Free Report)

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.